Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 591-596

  Park, Jeong M ^a   Lake, Kathleen D ^a,b   Cibrik, Diane M ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cyclosporine; Diabetes; Mycophenolic acid; Pharmacokinetics; Tacrolimus

Indexed keywords

BETA GLUCURONIDASE; CYCLOSPORIN A; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; CYCLOSPORIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; PRIORITY JOURNAL; THERAPY EFFECT; BLOOD; COMPARATIVE STUDY; COMPLICATION; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 1; DRUG INTERACTION; KIDNEY TRANSPLANTATION; MIDDLE AGED; PHYSIOLOGY; TRANSPLANTATION;

ADULT; CROSS-OVER STUDIES; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TRANSPLANTATION;

EID: 55349083359     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181858169     Document Type: Article

References (36)

1. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patient receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol. 1997;5:225-232.
2. Hübner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539.
3. Smak Gregoor PJH, de Sévaux RGL, Hené RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
4. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23: 35-38.
5. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit. 2001;23:717-721.
6. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
7. Kobayashi M, Saitoh H, Tadano K, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
8. Hesseling DA, van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
9. Meier-Kriesche HU, Chu AH, David KM, et al. Switching immunosuppression medications after renal transplantation - a common practice. Nephrol Dial Transplant. 2006;21:2256-2262.
10. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
11. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100-104.
12. Mourad M, Malaise J, Eddour DC, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248.
13. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolate acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006;82:1004-1012.
14. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007. Available at: http://www.usrds.org/2007/ ref/B_prevalence_07.pdf. Accessed January 23, 2008.
15. Cohen DJ, St. Martin L, Christensen LL, et al. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant. 2006;6:1153-1169.
16. Horowitz M, O'Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med. 2002;19:177-194.
17. Pescovitz MD, Gausch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3:1581-1586.
18. van Hest RM, Mathôt RAA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit. 2004;26:620-625.
19. Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit. 2006;28:95-101.
20. Naesens M, Vwebeke K, Vanrenterghem Y, et al. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. Br J Clin Pharmacol. 2006;63:541-547.
21. Costa A, Alessiani M, De Ponti F, et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. Transplant Proc. 1996;28:2571-2572.
22. Maes BD, Vanwalleghem J, Kupers D, et al. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation. 1999;68:1482-1485.
23. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
24. Annesley TM, Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin Chem. 2004;50:1845-1848.
25. Annesley TM. Application of commercial calibrators for the analysis of immunosuppressant drugs in whole blood. Clin Chem. 2005;51:457-460.
26. Gwilt RR, Nahhas RR, Tracewell WG, et al. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477-490.
27. Zanker B, Sohr B, Eder M, et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Transplant Proc. 1999;31:1167.
28. Kaplan B, Meier-Kriesche H-U, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant. 2005;19:551-558.
29. van Hest RM, Mathot RAA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
30. Kuypers DRJ, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronsyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
31. Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-1084.
32. Weimert NA, DeRotte M, Alloway RR, et al. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit. 2007;29:141-149.
33. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safery and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
34. Glander P, Hambach P, Braun KP, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther. 2003;41:470-476.
35. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051.
36. Patel CG, Richman K, Yang D, et al. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit. 2007;29:735-742.